Design Therapeutics Inc Stock News

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027  Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong financial runway CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Design Ther...

GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1...

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m.

Design Therapeutics shares ran up early Monday on positive results in Friedreich's ataxia. And then, the biotech stock lost it all.

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing

CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast...

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and Securities of $222.8 Million at Quarter-End Provide Runway to Support Ongoing Clinical Execution CARLSBAD, Calif.